Jazz Pharmaceuticals Sees FY 2012 Adjusted EPS of $4.00 – 4.15 vs $3.40 Est
Jazz Pharmaceuticals (Nasdaq: JAZZ) today provided full year financial guidance for 2012 reflecting the planned business combination with Azur Pharma Public Limited Company, which the companies are targeting to close during the week of January 16, 2012. The company also announced that the Hart-Scott-Rodino waiting period has expired.
Total revenues: $465 – 490 million
Adjusted net income per diluted share $4.00 – 4.15
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.